Project
A multicenter, non-randomized, open-label phase 1b study to determine the maximum tolerated and recommended phase 2 dose of the ATR Inhibitor BAY 1895344 in combination with pembrolizumab and characterize its safety, tolerability, pharmacokinetics and preliminiary anti-tumor activity in patients with advanced solid tumors
Automatically Closed · 2021 until 2022
Jörger Markus
Type
Clinical Studies
Range
Multicentric, KSSG as main centre
Units
Status
Automatically Closed
Start Date
2021
End Date
2022
Financing
Industry
Study Design
Phase Ib
Keywords
ATM
Partner
Bayer
Brief description/objective
BAY-1895344 und Pembrolizumab bei ausgewählten Tumoren
mit genetischen Alterationen von ATM.